Opdyta (Nivolumab) is a human programmed death receptor-1 (PD-1) blocking antibody.
Opdyta is used;
For the treatment of patients with unresectable or metastatic melanoma and disease progression in combination with ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor.
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Or in combination with ipilimumab as a first-line treatment whose tumors express PD-L1, with no EGRF or ALK genomic tumor abnormalities.
Treatment of advanced renal cell cancer in patients who have received prior anti-angiogenic therapy. Or in combination with Ipilimumab.
Treatment of patients with classical Hodgkins lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin.
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.
Treatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
Treatment of metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.
For the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors or colorectal cancer that have progressed following prior treatment.
For the treatment of patients with hepatocellular cancer (HCC) who have been previously treated with sorafenib.
For patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy
